|
|
|
|
|
Legal status
Patent revoked (after opposition at EPO)
| (51) | INT.CL. | A61K 31/137 | (2006.01) |
| A61P 37/00 | (2006.01) | ||
| A61P 37/06 | (2006.01) | ||
| A61K 31/135 | (2006.01) | ||
| A61K 31/138 | (2006.01) | ||
| A61K 31/661 | (2006.01) |
| (11) | Number of the document | 3409274 |
| (13) | Kind of document | T |
| (96) | European patent application number | 18179301.9 |
| Date of filing the European patent application | 2009-12-21 | |
| (97) | Date of publication of the European application | 2018-12-05 |
| (45) | Date of publication and mention of the grant of the patent | 2019-11-20 |
| (46) | Date of publication of the claims translation | 2020-02-10 |
| (30) | Number | Date | Country code |
| 139672 P | 2008-12-22 | US | |
| 218530 P | 2009-06-19 | US | |
| 246715 P | 2009-09-29 | US |
| (72) |
Schmouder, Robert, US
Dumortier, Thomas, CH
David, Olivier, CH
Looby, Michael, CH
|
| (73) |
Novartis AG,
Lichtstrasse 35, 4056 Basel,
CH
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | Dozavimo schema S1P receptoriaus agonistui |
| DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST |
| Payment date | Validity (years) | Amount | |
| 2024-11-22 | 16 | 347.00 EUR |
| Patent revoked (after opposition at EPO) | ||
| Invalidation date | 2024-11-27 |